Hepatology Journal

•  
• Overview
•  
• Identity
•  
• View All
•  

Overview

publication venue for

• RE- EVALUATING THE 6 MONTH RULE PRIOR TO LIVER TRANSPLANT: A CLINICAL PRACTICE GUIDELINE 2023
• IDENTIFICATION AND CHARACTERIZATION OF A NOVEL PHENYL-BIS (ALKYLIDENECARBOXYLIC ACID) THAT REDUCES HEPATOCELLULAR CARCINOMA (HCC) AND SYNERGIZES WITH SORAFENIB 2022
• PRIOR THERAPY WITH SOFOSBUVIR/VELPATASVIR ASSOCIATED WITH REDUCED RESPONSE TO SOFOSBUVIR/VELPATASVIR/VOXILAPREVIR: RESULTS FROM A CANADIAN PROSPECTIVE REGISTRY 2019
• Sofosbuvir/Velpatasvir for 12 Weeks Is Safe and Effective in Patients Undergoing Dialysis 2018
• Effectiveness of Sofosbuvir/Velpatasvir for 12 Weeks in HCV Genotype 3 Patients with Compensated Cirrhosis in Clinical Practice Cohorts from Around the World 2018
• Identification of Novel HCV Genotype and Subtypes in Patients Treated with Sofosbuvir Based Regimens 2017
• A Randomized Phase 3 Trial of Sofosbuvir/Velpatasvir/Voxilaprevir for 8 Weeks and Sofosbuvir/Velpatasvir for 12 Weeks for Patients with Genotype 3 HCV Infection and Cirrhosis: The POLARIS-3 Study 2016
• Macrophages are the gateway to damaging viral replication in Coronavirus infection 2016
• Metformin targets a phosphoSTAT3-miRNAs pathway to inhibit lipid droplets accumulation and intracellular inflammation in vitro and in vivo 2015
• Identifying the disease burden of hepatitis C virus (HCV) infection and non-injection drug use: a systematic review and meta-analysis of persons who use drugs but do not inject 2014
• Effects of bariatric surgery on severe liver injury in morbid obese patients with proven NASH: a prospective study 2014
• Hepatitis B core antigen expression in liver predicts HBeAg seroconversion in HBeAg positive chronic hepatitis B with pegylated interferon α-2a therapy 2013
• Serum ceruloplasmin levels correlate negatively with stages of liver pathology and can be used in a new noninvasive model for predicting liver fibrosis in chronic hepatitis B-virus related liver disease 2013
• Incidence and characteristics of autoimmune hepatitis in children and adolescents in Canada: A preliminary report of The Canadian Pediatric Hepatology Research Group 2012
• Selective alpha v integrin deletion identifies a core, targetable molecular pathway that regulates fibrosis across solid organs 2012
• 72 WEEKS OF PEG-IFN IS MORE EFFICACIOUS THAN 48 WEEKS IN HBEAG-POSITIVE PATIENTS IN CHINA 2011
• A GENOME WIDE CHROMATIN-IMMUNOPRECIPITATION (CHIP-SEQ) STUDY TO IDENTIFY HBX CELLULAR TARGET GENES AND TRANSCRIPTIONAL PARTNERS IN HBV REPLICATING HCC CELLS 2011
• A RANDOMIZED, CONTROLLED PHASE 2 CLINICAL TRIAL OF JX-594, A TARGETED MULTI-MECHANISTIC ONCOLYTIC POXVIRUS, IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA: FINAL DATA 2011
• MODELING LIVER DISEASE OUTCOME IN AN INTERNATIONAL MULTI-CENTER COHORT OF ALAGILLE SYNDROME PATIENTS 2011
• THE PREVALENCE AND METABOLIC SIGNIFICANCE OF NONALCOHOLIC FATTY LIVER DISEASE IN ADOLESCENT GIRLS WITH POLYCYSTIC OVARY SYNDROME 2011
• GENOME WIDE IDENTIFICATION OF HBX CELLULAR TARGET GENES AND TRANSCRIPTIONAL PARTNERS IN HBV REPLICATING HCC CELLS BY CHIP-SEQ 2010
• NON-INVASIVE DIAGNOSIS OF ESOPHAGEAL VARICES IN CHILDREN: A PROSPECTIVE, MULTICENTRE, VALIDATION STUDY 2010
• DETERMINANTS OF VIROLOGIC RELAPSE FOLLOWING HEPATITIS C ANTIVIRAL THERAPY: ANALYSIS OF THE CANADIAN POWER PROGRAM 2009
• EXTENDED TREATMENT WITH PEGINTERFERON ALFA-2A BENEFITS PATIENTS WITH HBEAG-POSITIVE CHRONIC HEPATITIS B WITH A PARTIAL RESPONSE AFTER 48 WEEKS OF THERAPY - CLINICAL EXPERIENCE FROM A CHINESE CENTER 2009
• OUTCOMES OF A LARGE, INCLUSIVE POPULATION-BASED HEPATITIS C TREATMENT PROGRAM ARE SIMILAR TO RANDOMIZED CONTROLLED TRIALS: INTERIM RESULTS OF THE CANADIAN REDIPEN PROGRAM 2009
• PEGINTERFERON ALPHA-2A MAY ACHIEVE HIGHER SUSTAINED VIROLOGICAL RESPONSE THAN PEGINTERFERON ALPHA-2B IN CHRONIC HEPATITIS C: A COCHRANE SYSTEMATIC REVIEW OF RANDOMIZED CLINICAL TRIALS 2009
• TRANSIENT ELASTOGRAPHY (FIBROSCAN) IN CHRONIC HEPATITIS B INFECTION: REDUCE NUMBER OF BIOPSIES & SAVE MONEY 2009
• PROSPECTIVE EVALUATION OF LIVER BIOCHEMISTRY IN CHILDREN WITH TURNER SYNDROME: HIGH PREVALENCE OF ABNORMALITIES ASSOCIATED WITH CELIAC DISEASE AND INSULIN RESISTANCE 2008
• TRANSCRIPTIONAL REPRESSION OF P53-PARALOG DNP73 ONCOGENE BY alpha-IFN/STAT2 2008
• Chromatin-based analysis of the IFN alpha transcriptome reveals functionally distinct subsets of STAT2 direct target genes 2007
• Consistency of sustained virologic response (SVR) across weight categories: Results from the Canadian power (peginterferon alfa-2B prospective optimal weight-based dosing response) program 2007
• Liver adaptation to ischemia: Novel evidence for an alternative ATP-generating metabolic pathway 2007
• An interim analysis of the Canadian power program (PEGinterferon alfa-2b prospective optimal weight-based dosing response): Consistent SVR rates across all weight categories 2006
• Exposure to ribavirin (RBV) predicts EVR and SVR in patients with HCV genotype 1 infection: Analysis of the Canadian pegasys expanded access program (EAP) 2006
• Are HFE gene mutations and iron overload related to nonalcoholic steatohepatitis in petrochemical workers? 2002
• Nonalcoholic steatohepatitis in petrochemical workers: Follow up of those removed from exposure area and those who remained. 2002
• Nonalcoholic steatohepatitis: Clinic-pathologic profile in petrochemical workers and in the individuals not exposed. 2002
• Recombinant activated factor VII in children with liver disease and coagulopathy. A preliminary study. 2001
• Health-related quality of life in hepatitis C measured by generic, disease-specific and utility instruments. 1999
• Extensive evaluation of quality of life (QOL) in a large cohort of patients with a variety of chronic liver diseases 1998
• Performance of new disease-specific quality of life instrument in cholestatic liver disease 1998
• A liver disease-specific health related quality of life index: Chronic liver disease questionnaire (CLDQ) 1997
• Splenic function in obstructive jaundice: A clinical and experimental study. 1997
• Role of increased biliary pressure in hepatocellular injury associated with segmental bile duct obstruction. 1996
• Increased affinity of peripheral benzodiazepine receptors in alcoholic liver cirrhosis 1996
• PROPRANOLOL IN THE PREVENTION OF REBLEEDING FROM PORTAL HYPERTENSIVE GASTROPATHY - A MULTICENTER RANDOMIZED CONTROLLED TRIAL 1990
• HEMODYNAMIC EVENTS IN A PROSPECTIVE RANDOMIZED TRIAL OF PROPRANOLOL VS PLACEBO IN THE PREVENTION OF THE 1ST VARICEAL HEMORRHAGE 1988
• PROPRANOLOL IN THE PREVENTION OF 1ST HEMORRHAGE FROM ESOPHAGEAL-VARICES (EVH) - A MULTICENTER CONTROLLED TRIAL 1988
• ALTERATION IN HEPATIC ORGANELLE FUNCTION IN INHERITED COPPER-OVERLOAD 1984
• Model to predict major complications following liver resection for HCC in patients with metabolic syndrome.  77:1527-1539. 2023
• Paraneoplastic Polyarthritis in Hepatocellular Carcinoma Treated With Lenvatinib.  74:1705-1707. 2021
• A practical approach to nutritional screening and assessment in cirrhosis.  65:1044-1057. 2017
• A practical approach to nutritional screening and assessment in cirrhosis..  65:1044-1057. 2017
• Esophageal balloon tamponade versus esophageal stent in controlling acute refractory variceal bleeding: A multicenter randomized, controlled trial.  63:1957-1967. 2016
• The architecture of diagnostic research: From bench to bedside-research guidelines using liver stiffness as an example.  60:408-418. 2014
• Reply:.  53:1407-1407. 2011
• Reply:.  52:2241-2241. 2010
• Liver-specific suppressor of cytokine signaling-3 deletion in mice enhances hepatic insulin sensitivity and lipogenesis resulting in fatty liver and obesity1.  52:1632-1642. 2010
• Reply: Methodological issues in a meta-analysis.  52:396-397. 2010
• Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: Systematic review of randomized trials.  51:1176-1184. 2010
• The novel CD4+CD25+ regulatory T cell effector molecule fibrinogen-like protein 2 contributes to the outcome of murine fulminant viral hepatitis.  49:387-397. 2009
• Body fat distribution, relative weight, and liver enzyme levels: A population-based study.  39:754-763. 2004
• TIPS versus drug therapy in preventing variceal rebleeding in advanced cirrhosis: A randomized controlled trial.  35:385-392. 2002
• Multicenter Randomized Controlled Trial of Terlipressin Versus Sclerotherapy in the Treatment of Acute Variceal Bleeding: The TEST Study.  32:471-476. 2000
• Molecular mechanisms of tumor necrosis factorα–stimulated leukocyte recruitment into the murine hepatic circulation.  31:1123-1127. 2000
• Evidence-based medicine: A method for solving clinical problems in hepatology.  30:829-832. 1999
• Hemochromatosis C282Y mutation and histological fibrosis in patients with C virus chronic hepatitis.  29:1338-1338. 1999
• Budd-chiari syndrome in patients with hematological disease: A therapeutic challenge.  27:1157-1161. 1998
• Therapeutic serum concentrations of human alpha-1-antitrypsin after adenoviral-mediated gene transfer into mouse hepatocytes..  21:815-819. 1995
• Propranolol in the prevention of the first hemorrhage from esophagogastric varices: A multicenter, randomized clinical trial.  13:902-912. 1991
• The demography of primary biliary cirrhosis in ontario, canada.  12:98-105. 1990
• Vasopressin/nitroglycerin infusion vs. esophageal tamponade in the treatment of acute variceal bleeding: A randomized controlled trial.  11:964-968. 1990
• Balloon tamponade vs. endoscopic sclerotherapy: In the management of active variceal hemorrhage.  11:898-899. 1990
• Association of transdermal nitroglycerin to vasopressin infusion in the treatment of variceal hemorrhage: A placebo-controlled clinical trial.  10:962-968. 1989
• Response to Treatment as a Predictor of Hepatocellular Carcinoma (hcc) Development among Persons Chronically Infected with Hepatitis C Virus (hcv) Infection: A Meta-analysis.  56:648A-649A.

has subject area

• 1101 Medical Biochemistry and Metabolomics (FoR)
• 1103 Clinical Sciences (FoR)
• 1107 Immunology (FoR)
• Gastroenterology & Hepatology (Science Metrix)

Identity

International Standard Serial Number (ISSN)

• 0270-9139

Electronic International Standard Serial Number (EISSN)

• 1527-3350